Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC1101 combination therapy in KRAS G12D-mutant advanced solid tumors (Ib/II)
CTR20251998Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLC1101 in Nonhematologic neoplasms, sponsored by Qilu Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
QLC1101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251998.